Company · CIK 0001889109 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
BELITE BIO, INC · BLTE
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 SForm 4 → | Sep 9, 7:39 pm EDT | Yu-Hsin LinChief Executive Officer, Director | 100,435 | $190.00 | $19,082,549 | 70,134 | −58.9% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 9, 7:38 pm EDT | Hao-Yuan ChuangChief Financial Officer, Director | 67,395 | $189.98 | $12,803,528 | 26,038 | −72.1% | 10b5-1 |
| Aug 12, 2026 SForm 4 → | Aug 14, 6:10 am EDT | Hao-Yuan ChuangChief Financial Officer, Director | 367 | $180.35 | $66,187 | 93,433 | −0.39% | 10b5-1 |
| Aug 12, 2026 SForm 4 → | Aug 14, 6:10 am EDT | Yu-Hsin LinChief Executive Officer, Director | 365 | $180.35 | $65,827 | 170,569 | −0.21% | 10b5-1 |
| Jun 18, 2026 SForm 4 → | Jun 22, 6:05 am EDT | Hendrik Peter SchollChief Medical Officer | 10,000 | $145.24 | $1,452,435 | 15,000 | −40.0% | |
| Jun 16, 2026 SForm 4 → | Jun 17, 6:03 am EDT | Hendrik Peter SchollChief Medical Officer | 10,000 | $140.57 | $1,405,729 | 25,000 | −28.6% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.